Navigation Links
Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
Date:11/4/2011

p>Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, holds an exclusive license to develop and commercialize JX-594 in Europe and neighboring countries. Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, holds an exclusive license to develop and commercialize JX-594 in South Korea, and Lee's Pharmaceutical Ltd. holds an exclusive license to develop and commercialize JX-594 in China.

Transgene, a member of the Institut Merieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases, and has five compounds in clinical development: TG4010 and JX-594 (TG6006) having completed initial phase II trials, TG4001 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with U.S.-based Jennerex Biotherapeutics, Inc., to develop and market JX-594 (TG6006), an oncolytic product. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available on the internet at www.transgene.fr.

Green Cross Corp. is a publicly traded and leading Korean biopharmaceutical company specialized in development and commercialization of vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies in oncology and infectious diseases. Green Cross Corp. has been collaborating with Jennerex in Korea since 2006 to jointly conduct the Phase 1 and 2 clinical trials in patients with liver cancer. Additional information about Green Cr
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  ArroGen Group, an integrated ... Fingerprint Molecular Identification™ (FMID) technology Aug. 2-8 at ... Sacramento, Calif. ... enable law enforcement agents, district attorneys and government ... suspects. By analyzing chemical residues on ...
(Date:8/3/2015)... Mass. , Aug. 3, 2015  Merck KGaA, ... for innovative and top-quality high-tech products in the healthcare, ... with the US-based company Nano-C, their development and launch ... of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... in the growing OPV sector. Novel derivatives: ...
(Date:8/3/2015)... GERMANTOWN, Md. , Aug. 3, 2015   ... it will release first half and second quarter 2015 ... 10 th , 2015.  The Company will host a ... results and provide a general business update. ... (Domestic US) and 1-412-902-4262 (International), and asking to join ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... Attorney,s, Office for Eastern District of Pennsylvania and U.S. ... Settles State Cases with Connecticut and Massachusetts, ... announced today it has finalized a previously announced agreement ... District of,Pennsylvania, the U.S. Department of Justice and various ...
... SAN FRANCISCO, CALIF., Sept. 29 diaDexus, Inc.,today ... (LHF), a,non-profit organization dedicated to combating cardiovascular disease ... will be included as part,of the LHF,s cardiovascular ... individuals at elevated risk for suffering a heart,attack ...
... individuals of all ages who,have reached beyond the ... ATLANTA, Sept. 29 UCB today announced the ... which this year awarded a,total of $300,000 in ... scholarship program was established to recognize individuals,of all ...
Cached Biology Technology:Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 3Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 4diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players 2UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 2UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 3UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 4UCB Scholarship Program Awards $300,000 to Students Living with Crohn's Disease 5
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... invading virus hijacks a cell,s workings by imitating a ... cell signals, the virus destroys a defensive protein designed ... cell cultures, may represent a broader targeting strategy used ... for developing more effective treatments for infectious diseases. ...
... staff scientist Greg Asner has been selected as one of ... the Energy and Climate Partnership of the Americas (ECPA) through ... experts from the academic, non-profit, and private sectors in the ... throughout the Western Hemisphere. Fellows will work with local government ...
... , New York, N.Y. (March 26, 2012) Autism ... today announced the award of new research grants totaling ... "Suzanne and I are extraordinarily proud of Autism Speaks, ... potential to open new avenues to understanding autism," said ...
Cached Biology News:To drive infections, a hijacking virus mimics a cell's signaling system 2Carnegie's Greg Asner named Energy/Climate Fellow by US State Department 2Autism Speaks awards $1.1 million to fund high priority studies 2Autism Speaks awards $1.1 million to fund high priority studies 3
...
... Life Science FLA-5100 imaging system allows imaging ... as 40 x 46cm at a pixel ... system is especially suitable for protein electrophoresis ... analysis for genomics., Fuji s FLA-5100 includes ...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
Biology Products: